Research Article| Volume 54, ISSUE 1, P11-18, April 20, 2006

Download started.


Risk of stroke and hormone replacement therapy

A prospective cohort study



      The purpose of this study was to examine the risk of first-ever stroke in relation to use of hormone replacement therapy (HRT) among middle-aged and older Swedish women.


      A total of 16,906 women, 45–73 years old, from the ‘Diet and Cancer’ study in Malmö, Sweden were examined. Women were considered as HRT users if they took systemic hormone therapy regularly. Incidence of stroke was followed for a mean period of 10.5 years.


      In all, 2148 (12.7%) women used HRT. A total of 461 stroke cases occurred during follow-up, 48 of them in HRT users. Incidence of total stroke and ischemic subtype had no significant relation to HRT use. However, an increased risk of hemorrhagic stroke was found in women taking unopposed estrogen (RR = 2.55, 95%CI: 1.03–6.35) or un-native estrogen regimens (RR = 4.27, 95%CI: 1.71–10.66). Although not significantly, the risk of stroke was 33% lower in women who started their treatment before menopause. Among HRT users, the risk of stroke was associated with advancing age, smoking, excess body weight and hypertension.


      There is no significant association between hormone therapy and risk of total stroke in women during 10.5 years follow-up. Preparations of estrogen and time for initiation of treatment may affect the risk of stroke.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Manson J.E.
        • Hsia J.
        • Johnson K.C.
        • Rossouw J.E.
        • Cushman M.
        Estrogen plus progestin and the risk of coronary heart disease.
        N Engl J Med. 2003; 349: 523-534
        • Wassertheil-Smoller S.
        • Hendrix S.L.
        • Limacher M.
        • et al.
        Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative. A randomized trial.
        JAMA. 2003; 289: 2673-2684
        • Bath P.M.W.
        • Gray L.J.
        Association between hormone replacement therapy and subsequent stroke: a meta-analysis.
        BMJ. 2005; 21: 1-4
        • Grodstein F.
        • Manson J.E.
        • Colditz G.A.
        • Willett W.C.
        • Speizer F.E.
        • Stampfer M.J.
        A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
        Ann Intern Med. 2000; 133: 933-941
        • Finucane F.F.
        • Madans J.H.
        • Bush T.L.
        • Wolf P.H.
        • Kleinman J.C.
        Decreased risk of stroke among postmenopausal hormone users.
        Arch Intern Med. 1993; 153: 73-79
        • Falkeborn M.
        • Persson I.
        • Terent A.
        • Adami H.O.
        • Lithell H.
        • Bergstrom R.
        Hormone replacement therapy and the risk of stroke.
        Arch Intern Med. 1993; 153: 1201-1209
        • Berglund G.
        • Elmståhl S.
        • Janzon L.
        • Larsson S.A.
        Design and feasibility.
        J Intern Med. 1993; 233: 45-51
        • Jerntorp P.
        • Berglund G.
        Stroke registry in Malmö.
        Stroke. 1992; 23: 357-361
        • Rosvall M.
        • Ostergren P.O.
        • Hedblad B.
        • Berglund G.
        Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women.
        Am J Epidemiol. 2000; 152: 334-346
      1. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413–46.

        • Grodstein F.
        • Clarkson T.B.
        • Manson J.E.
        Understanding the divergent data on postmenopausal hormone therapy.
        N Engl J Med. 2003; 348: 645-650
        • Lemaitre R.N.
        • Heckbert S.R.
        • Psaty B.M.
        • Smith N.L.
        • Kaplan R.C.
        • Longstreth Jr., W.T.
        Hormone replacement therapy and associated risk of stroke in postmenopausal women.
        Arch Intern Med. 2002; 162: 1954-1960
        • Paganini-Hill A.
        Hormone replacement therapy and stroke: risk, protection or no effect?.
        Maturitas. 2001; 38: 243-261
        • Simon J.A.
        • Hsia J.
        • Cauley J.A.
        • et al.
        Postmenopausal hormone therapy and risk of stroke.
        Circulation. 2001; 103: 638-642
        • Kiechl S.
        • Willeit J.
        The natural course of atherosclerosis.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1484-1490
        • Hodis H.N.
        • Mack W.J.
        • Lobo R.A.
        • et al.
        Estrogen in the prevention of atherosclerosis.
        Ann Intern Med. 2001; 135: 939-953
        • Angerer P.
        • Stork S.
        • Kothny W.
        • Schmitt P.
        • von Schacky C.
        Effect of oral postmenopausal hormone replacement on progression of atherosclerosis.
        Arterioscler Thromb Vasc Biol. 2001; 21: 262-268
        • Mueck A.O.
        • Seeger H.
        Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women.
        Maturitas. 2004; 49: 189-203
        • Wren B.G.
        • Routledge D.A.
        Blood pressure changes: oestrogens in climacteric women.
        Med J Aust. 1981; 2: 528-531
        • L’hermit M.
        Risks of estrogens and progestogens.
        Maturitas. 1990; 12: 215-246
        • Li C.
        • Engstrom G.
        • Hedblad B.
        • Berglund G.
        • Janzon L.
        Blood pressure control and risk of stroke.
        Stroke. 2005; 36: 725-730